Portola Pharmaceuticals Inc. said Tao Fu resigned as executive vice president and chief commercial and business officer, effective Sept. 21, to pursue other opportunities.
South San Francisco, Calif.-based Portola said that Interim co-President and CFO Mardi Dier will lead its commercial activities, including the ongoing launches of blood disorder therapies Andexxa and Bevyxxa.
Fu will remain as a consultant until March 1, 2019, to assist in the transition.
The company said in a Sept. 7 news release that it has hired an executive search firm for recruiting a new CEO and chief commercial officer. Portola's CEO retired in August.
Portola is a biopharmaceutical company that develops and commercializes therapeutics relating to blood clotting and other blood disorders.